Augmentation of NAD⁺ by Dunnione Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis in Mice

References

• Bochenska K, Smolinska E, Moskot M, Jakobkiewicz-Banecka J, Gabig-Ciminska M. Models in the Research Process of Psoriasis. Int J Mol Sci. 2017;18(12):2514.
   PubMed Web of Science ®Google Scholar
• Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33(1):13–23.
   PubMed Web of Science ®Google Scholar
• Liu T, Li S, Ying S, et al. The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: from Bench to Bedside. Front Immunol. 2020;11:594735.
   PubMed Web of Science ®Google Scholar
• Furue M, Furue K, Tsuji G, Nakahara T. Interleukin-17A and Keratinocytes in Psoriasis. Int J Mol Sci. 2020;21(4):1275.
   PubMed Web of Science ®Google Scholar
• Zapata-Perez R, Wanders RJA, van Karnebeek CDM, Houtkooper RH. NAD(+) homeostasis in human health and disease. EMBO Mol Med. 2021;13(7):e13943.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang F, Ding J. As a Modulator, Multitasking Roles of SIRT1 in Respiratory Diseases. Immune Netw. 2022;22(3):e21.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Oh GS, Shen A, et al. Augmentation of NAD(+) by NQO1 attenuates cisplatin-mediated hearing impairment. Cell Death Dis. 2014;5:e1292.
   PubMed Web of Science ®Google Scholar
• Singh V, Ubaid S. Role of Silent Information Regulator 1 (SIRT1) in Regulating Oxidative Stress and Inflammation. Inflammation. 2020;43(5):1589–1598.
   PubMed Web of Science ®Google Scholar
• Ke Y, Wang C, Zhang J, et al. The Role of PARPs in Inflammation-and Metabolic-Related Diseases: molecular Mechanisms and Beyond. Cells. 2019;8(9):1047.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Pandit A, Oh GS, et al. Dunnione ameliorates cisplatin ototoxicity through modulation of NAD(+) metabolism. Hear Res. 2016;333:235–246.
   PubMed Web of Science ®Google Scholar
• Shen A, Kim HJ, Oh GS, et al. NAD(+) augmentation ameliorates acute pancreatitis through regulation of inflammasome signalling. Sci Rep. 2017;7(1):3006.
   PubMed Web of Science ®Google Scholar
• Oh GS, Kim HJ, Choi JH, et al. Pharmacological activation of NQO1 increases NAD(+) levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney Int. 2014;85(3):547–560.
   PubMed Web of Science ®Google Scholar
• Pandit A, Kim HJ, Oh GS, et al. Dunnione ameliorates cisplatin-induced small intestinal damage by modulating NAD(+) metabolism. Biochem Biophys Res Commun. 2015;467(4):697–703.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018;201(6):1605–1613.
   PubMed Web of Science ®Google Scholar
• van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182(9):5836–5845.
   PubMed Web of Science ®Google Scholar
• Katsyuba E, Romani M, Hofer D, Auwerx J. NAD(+) homeostasis in health and disease. Nat Metab. 2020;2(1):9–31.
   PubMedGoogle Scholar
• Hwang JH, Kim DW, Jo EJ, et al. Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice. Diabetes. 2009;58(4):965–974.
   PubMed Web of Science ®Google Scholar
• Jo IG, Park D, Kyung J, et al. Inhibitory effects of a beta-dunnione compound MB12662 on gastric secretion and ulcers. Lab Anim Res. 2013;29(3):178–181.
   PubMedGoogle Scholar
• Khadka D, Kim HJ, Oh GS, et al. Augmentation of NAD(+) levels by enzymatic action of NAD(P)H quinone oxidoreductase 1 attenuates Adriamycin-induced cardiac dysfunction in mice. J Mol Cell Cardiol. 2018;124:45–57.
   PubMed Web of Science ®Google Scholar
• Chiang CC, Cheng WJ, Korinek M, Lin CY, Hwang TL. Neutrophils in Psoriasis. Front Immunol. 2019;10:2376.
   PubMed Web of Science ®Google Scholar
• Hurtado-Bages S, Knobloch G, Ladurner AG, Buschbeck M. The taming of PARP1 and its impact on NAD(+) metabolism. Mol Metab. 2020;38:100950.
   PubMed Web of Science ®Google Scholar
• Murata MM, Kong X, Moncada E, et al. NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival. Mol Biol Cell. 2019;30(20):2584–2597.
   PubMed Web of Science ®Google Scholar
• Martinez-Morcillo FJ, Canton-Sandoval J, Martinez-Navarro FJ, et al. NAMPT-derived NAD+ fuels PARP1 to promote skin inflammation through parthanatos cell death. PLoS Biol. 2021;19(11):e3001455.
   PubMed Web of Science ®Google Scholar
• Kiss B, Szanto M, Hegedus C, et al. Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis. Exp Dermatol. 2020;29(1):79–85.
   PubMed Web of Science ®Google Scholar
• Hassa PO, Haenni SS, Elser M, Hottiger MO. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev. 2006;70(3):789–829.
   PubMed Web of Science ®Google Scholar
• Sun W, Gao Y, Yu X, et al. ‘Psoriasis 1’ reduces psoriasislike skin inflammation by inhibiting the VDRmediated nuclear NFkappaB and STAT signaling pathways. Mol Med Rep. 2018;18(3):2733–2743.
   PubMedGoogle Scholar
• Tang L, Li T, Zhang B, et al. Punicalagin Alleviates Psoriasis by Inhibiting NF-kappaB-Mediated IL-1beta Transcription and Caspase-1-Regulated IL-1beta Secretion. Front Pharmacol. 2022;13:817526.
   PubMed Web of Science ®Google Scholar
• Moorchung N, Kulaar JS, Chatterjee M, Vasudevan B, Tripathi T, Dutta V. Role of NF-kappaB in the pathogenesis of psoriasis elucidated by its staining in skin biopsy specimens. Int J Dermatol. 2014;53(5):570–574.
   PubMed Web of Science ®Google Scholar
• de Gregorio E, Colell A, Morales A, Mari M. Relevance of SIRT1-NF-kappaB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease. Int J Mol Sci. 2020;21(11):3858.
   PubMed Web of Science ®Google Scholar
• Wang A, Wei J, Lu C, et al. Genistein suppresses psoriasis-related inflammation through a STAT3-NF-kappaB-dependent mechanism in keratinocytes. Int Immunopharmacol. 2019;69:270–278.
   PubMed Web of Science ®Google Scholar
• Bugaut H, Aractingi S. Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies. Front Immunol. 2021;12:621956.
   PubMed Web of Science ®Google Scholar
• Nakajima K, Kataoka S, Sato K, et al. Stat3 activation in epidermal keratinocytes induces Langerhans cell activation to form an essential circuit for psoriasis via IL-23 production. J Dermatol Sci. 2019;93(2):82–91.
   PubMed Web of Science ®Google Scholar
• Xu F, Xu J, Xiong X, Deng Y. Salidroside inhibits MAPK, NF-kappaB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation. Redox Rep. 2019;24(1):70–74.
   PubMedGoogle Scholar